At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
In Brief
A Phase 2 clinical trial evaluating Carfilzomib, Lenalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 29 participants across 6 sites.
Detailed Summary
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients. In addition, the study is designed to test the amount of remaining myeloma cells in the body after treatment with higher carfilzomib doses which is known as minimal residual disease (MRD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsOnyx/Amgen, Celgene
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionOct 2024
TodayJul 2026
First PostedOct 18, 2016
Enrollment StartOct 1, 2016
Primary CompletionOct 8, 2024
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 9.7 years ago
Interventions
Carfilzomibdrug
Lenalidomidedrug
Dexamethasonedrug